September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
4 citations
,
January 1987 in “Beiträge zur Onkologie/Contributions to oncology” Adriamycin and ifosfamide together work best for advanced soft tissue sarcomas.
4 citations
,
October 2021 in “Scientific Reports” NKIRAS2 can suppress certain skin tumors but its effect on cancer varies with context and expression level.
123 citations
,
January 2012 in “The Keio Journal of Medicine” Anti-angiogenic therapy can help treat cancer but may cause resistance and side effects, so alternative methods are being explored.
1 citations
,
January 2023 in “SAGE open medical case reports” A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.
48 citations
,
July 2023 in “Pediatric Dermatology” Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
65 citations
,
October 2015 in “Acta Biomaterialia” The nano-carrier makes etoposide safer and more effective against lung cancer.
October 2021 in “International journal of basic and clinical pharmacology” Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
April 2023 in “Neurology” Valproic acid is a more effective treatment for vomiting in Alexander disease than other medications, with few side effects.
12 citations
,
September 2015 in “Drug Design Development and Therapy” AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
1 citations
,
May 2024 in “Pediatric Blood & Cancer” Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.
7 citations
,
March 2023 in “Lasers in Surgery and Medicine” Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.
February 2024 in “Frontiers in Cell and Developmental Biology” Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
7 citations
,
June 2007 in “AIDS” A man's hair loss was linked to his HIV medication, which improved after changing drugs.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
8 citations
,
August 2015 in “European Journal of Clinical Pharmacology” Rivaroxaban may cause hair loss.
January 2023 in “Applied sciences” Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Oral minoxidil can help regrow hair lost from antibody-drug conjugate treatment.
25 citations
,
March 2017 in “International Journal of Dermatology” Ruxolitinib effectively and safely regrows hair in alopecia patients.
March 2023 in “JAAD case reports” Dutasteride and minoxidil helped regrow hair in a woman with breast cancer.
20 citations
,
August 2008 in “Journal of Medical Case Reports” Ondansetron can cause serious allergic reactions, so use it carefully.
45 citations
,
October 2018 in “JCI Insight” Entospletinib effectively prevents eye and skin GVHD in mice.
65 citations
,
February 2011 in “Molecular cancer therapeutics” CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
1 citations
,
November 2011 in “Journal of AIDS & Clinical Research” Raltegravir may cause hair loss in some patients.
10 citations
,
November 2017 in “Letters in drug design & discovery” Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.
November 2018 in “Annals of oncology” A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.